Foresight Group Ltd Liability Partnership Takes Position in Genmab A/S Sponsored ADR $GMAB

Key Points

• Foresight Group Ltd Liability Partnership acquired a new stake in Genmab A/S by purchasing 48,725 shares, valued at approximately $954,000.
• Genmab's stock has experienced significant fluctuations, with a 1-year low of $17.24 and a high of $28.03, and currently opened at $27.73.
• Analyst ratings on Genmab vary, with one upgraded to "buy," although Zacks Research recently downgraded the stock from "strong-buy" to "hold."

Foresight Group Ltd Liability Partnership bought a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 48,725 shares of the company's stock, valued at approximately $954,000.

Several other institutional investors have also modified their holdings of the stock. Marotta Asset Management boosted its stake in shares of Genmab A/S by 5.8% in the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock worth $265,000 after acquiring an additional 739 shares during the last quarter. Gallacher Capital Management LLC boosted its holdings in Genmab A/S by 6.8% in the 1st quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company's stock valued at $281,000 after purchasing an additional 915 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after acquiring an additional 1,070 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Genmab A/S by 27.2% in the 1st quarter. Smartleaf Asset Management LLC now owns 5,772 shares of the company's stock valued at $115,000 after purchasing an additional 1,236 shares during the last quarter. Finally, Headlands Technologies LLC lifted its position in Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after buying an additional 1,464 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on GMAB shares. HC Wainwright upped their price target on Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Truist Financial raised their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Zacks Research lowered shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $39.25.

Genmab A/S Trading Up 0.8%

Shares of Genmab A/S stock traded up $0.23 on Tuesday, reaching $28.22. 499,022 shares of the stock were exchanged, compared to its average volume of 1,441,927. The business has a fifty day moving average price of $23.70 and a two-hundred day moving average price of $21.67. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $28.75. The firm has a market capitalization of $18.10 billion, a PE ratio of 14.18, a PEG ratio of 1.62 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The firm had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Research analysts expect that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.